The Questions I Would Ask Before Comparing Compounded GLP-1 Programs
By Marcus Reid — Sun Sep 27 2026
The Questions I Would Ask Before Comparing Compounded GLP-1 Programs — my honest, first-person take, backed by data from the 289 peptide vendors I track. Informational only; consult a licensed healthcare provider.
The Questions I Would Ask Before Comparing Compounded GLP-1 Programs ==================================================================
I spent years vetting compounding vendors, reading COAs, and calling pharmacies at odd hours so other people don’t have to learn the hard way. When I compare GLP-1 programs I look for specific, verifiable evidence — not glossy marketing language.
Why I start where others skip -----------------------------
In my vendor database I track 289 vendor profiles. Only 65 of those — 22% (65 of 289) — publish named‑lab Certificates of Analysis (COAs). That gap tells you everything: most programs will want to talk about quality, only a few will actually show you the paperwork. When you’re doing a glp-1 provider comparison, that paperwork is the first gate.
My three‑to‑five step checklist: the VET-GLP Checklist ------------------------------------------------------
I use a compact, repeatable framework I call the VET-GLP Checklist. It’s short so I actually use it on calls.
1. Verify COAs — named lab, batch-matched, recent date. 2. Evaluate clinical continuity — actual clinician follow-up, labs, and dose plans. 3. Trace compounding SOPs — pharmacy licensing, USP / practices, shipping controls. 4. Log telehealth cadence — how often they require live visits; where prescriptions originate.
If a program fails step 1 or 2, I stop asking price questions.
Top questions I ask (and why they matter) -----------------------------------------
- Do you publish named‑lab COAs for the specific batch you’ll ship? Why: Generic statements that “we test everything” are meaningless. I want a COA with the vendor name, lot number, assay methods, and the lab name. If they can’t or won’t provide it, treat that as a data point, not a negotiation starting point.
- Who actually writes the prescription and where are they licensed? Why: With many glp-1 telehealth models the prescribing clinician is in a different state, or the prescriber is a medical director who never sees you. I ask for the prescriber’s state license and specialty. Continuity matters; the worst outcomes I’ve tracked came from programs that delegated all monitoring to algorithms.
- How do you handle dose adjustments and adverse effects? Why: GLP‑1s commonly require titration. Does the program require follow-up visits or just let patients message a nurse? I prefer programs that lock in at least two scheduled follow-ups during titration.
- Can you show your compounding SOPs and licensing? Why: A licensed compounding pharmacy should be willing to summarize its USP compliance, sterility testing (if injectables), and shipping temperature controls. If they dodge specifics, that’s a red flag.
- What is your sourcing policy for active pharmaceutical ingredients (APIs)? Why: Where the API comes from, and whether it’s accompanied by vendor COAs, is a real safety question. Ask for the supplier name and country of origin.
- What does your after‑hours support look like? Why: Nausea, severe GI symptoms, or hypoglycemia concerns can arise during titration. I prefer programs that offer timely clinical access, not just a chat-bot.
- How do you handle returns, recalls, and batch notifications? Why: Compounded products can get recalled. The vendor should have a clear process for notifying patients and reclaiming product.
A short, practical comparison table -----------------------------------
| Green flag | Red flag | |---|---| | Named‑lab COA, batch matched | No COA, vague testing claims | | Prescriber licensed where patient lives | Prescriber never meets patient | | Scheduled titration visits | “Message if problems” only | | Clear shipping temperature control | No temp control described |
What I look for in glp-1 telehealth programs specifically --------------------------------------------------------
Telehealth can work, but it changes the risk calculus. For glp-1 telehealth I expect:
- An initial live visit (video preferred) with a clinician who documents baseline labs. - A written titration plan attached to the prescription. - Proactive follow-up at defined intervals (not “reach out if you feel bad”). - Clear escalation pathways to a local in‑person provider if needed.
If a telehealth program treats GLP‑1s like over‑the‑counter supplements, I close the tab.
On price, access, and the counter‑angle I always push ----------------------------------------------------
Conventional wisdom says: “Avoid compounded GLP‑1s — get the brand-name drug through a specialist.” I push back. That’s blanket advice that ignores nuance. In my experience, a properly documented compounded product with named‑lab COAs and solid clinical oversight can be a pragmatic choice for patients who need dose granularity or who can’t access branded drugs for cost reasons.
That said: “properly documented” is the key phrase. The majority of vendors I’ve tracked do not publish batch COAs, and I can’t recommend programs without them. Price alone is a poor proxy for quality; continuity of care and verifiable testing matter more to patient safety. If you must choose a compounded route, prioritize programs that clear my VET-GLP checklist over those offering the lowest price.
Where I go next when a program looks promising -----------------------------------------------
If a vendor passes the initial questions, my next steps are practical:
- Request the actual COA and scan it for assay methods and lab accreditation. - Confirm the prescriber’s license via the state board. - Ask for a written titration and monitoring plan I can save. - Run the vendor profile in my internal list at /vendors and cross-check any editorial notes. - If I’m still curious, I compare to my writeups at /best-glp1 and send people through the /glp1-quiz before they sign up.
Final, small but critical red flags ----------------------------------
- COAs dated more than six months ago with no batch number. - Shipping that relies on “standard overnight” in summer months without temperature data. - Vague language about “FDA‑approved ingredients” when the drug is compounded (FDA approval applies to the original manufactured product, not the compound). - No return or recall process.
A brief honest note on limits -----------------------------
I track vendor paperwork and clinical models — I’m not a prescriber. My focus is on documentation, process, and where risk is concentrated. If you’re comparing programs, let the presence (or absence) of named‑lab COAs and clinician follow-up steer you more than slick marketing or price.
*This article is for informational purposes only and is not medical advice. Consult a licensed healthcare provider before starting, changing, or obtaining a GLP‑1 medication.*
Frequently asked questions
How do I confirm the compounded GLP-1 is coming from a reputable source and is sterile and accurately dosed?
I’d ask the pharmacy for verifiable documentation: their licensing/accreditation, lot-specific certificates of analysis showing potency and purity, and results of sterility and endotoxin testing. I want to know their sterile-compounding processes, whether they do independent third‑party testing, and how they label beyond‑use dates and lot numbers so my prescriber can track recalls. I’d also confirm cold‑chain handling for shipment and ask for a clear chain-of-custody or shipping record before I accept treatment. for informational purposes only, not medical advice; consult a licensed healthcare provider before starting, changing, or obtaining a GLP-1 medication.
What should I look for about dosing, concentration, and how the product will be administered and monitored?
I’d ask how the product’s concentration is standardized (for example, exact mcg/mL), whether prefilled syringes or cartridges are used, and what instructions come with the product about preparation and administration. I want written prescribing guidance, clear conversion tables if concentrations differ from commercial formulations, and a monitoring plan from the clinician including how adverse effects will be reported and managed. If anything about dosing or administration is unclear, I wouldn’t proceed until my prescriber and the pharmacy provide clarification in writing. for informational purposes only, not medical advice; consult a licensed healthcare provider before starting, changing, or obtaining a GLP-1 medication.
How do I compare cost, supply reliability, and safety contingencies across compounded GLP-1 programs?
I’d compare total out‑of‑pocket cost (product, compounding fees, shipping, supplies like sharps and syringes), ask about typical lead times and backorder history, and request the pharmacy’s policy on damaged or spoiled shipments and lot recalls. I’d also confirm whether my insurer will cover any part and whether the pharmacy or clinic carries liability insurance and tracks adverse-event reports. Finally, I’d want a backup plan if the compound becomes unavailable so my care isn’t interrupted. for informational purposes only, not medical advice; consult a licensed healthcare provider before starting, changing, or obtaining a GLP-1 medication.
References
About the author
Marcus Reid: Marcus Reid spent a decade in software engineering before going deep into peptide research, product documentation, and the clinical literature. He writes about what the data and the paperwork actually say. He is not a doctor; PeptideTally content is educational and does not constitute medical advice.